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The incidence of ovarian cancer varies widely around the world,
with the highest rates in the developed countries of Europe and
North America, and the lowest in Africa and Asia (Parkin et al,
2002). In England and Wales, ovarian cancer is the most common
gynaecological cancer, and the fourth most common after cancers
of the breast, large bowel and lung, representing some 5% of all
cancers in women. It is rare in premenopausal women, with less
than 10% of cases arising under the age of 45.
The pattern of incidence for ovarian cancer with age is similar to
that of breast and uterine cancers, and they share some
reproductive risk factors. Late menarche, high parity, early
menopause and long-term use of combined oral contraceptives
all confer a lower risk of ovarian cancer, probably by reducing the
number of ovulatory cycles.
Incidence in England and Wales has increased gradually since
the early 1970s, especially in older women (Coleman et al, 1993),
but the upward trend in younger women appears to have reached a
plateau by the late 1990s (Quinn et al, 2001). Incidence is 5–10%
higher among women in more affluent groups than in the most
deprived group, and it increased further in these groups during the
1990s (data not shown). In the late 1990s, about 6000 women were
diagnosed with ovarian cancer in England and Wales each year.
Ovarian cancer accounts for 4000 deaths a year in England and
Wales, about 6% of all cancer deaths in women. In contrast to the
increasing trend in incidence, overall age-standardised mortality
has fallen slightly over the last decade, but a 20–30% fall in
mortality among women under 65 years has been balanced by an
increase of about 10% in mortality among older women. Survival
from ovarian cancer is the lowest among the gynaecological
cancers, because it is often at an advanced stage when diagnosed.
Some 81600 women were registered with an ovarian tumour in
England and Wales during the 14-year period 1986–1999,
but more than 6000 of these tumours were benign, of uncertain
behaviour, or metastatic to the ovary from a primary malignancy
elsewhere. Of the 75800 women resident in England and Wales
who were registered with a primary, malignant tumour of the
ovary, some 63800 were included in the analyses (84% of those
eligible). One percent of women were excluded because their vital
status was not known on 5 November 2002, when the data were
extracted for analysis and 10% because their recorded survival
time was zero (mainly death certificate only (DCO) cases whose
survival time was unknown). A further 3% were excluded because
it was not the woman’s first primary, invasive cancer, a previous
malignancy having been registered for the same woman at some
time since 1971. The proportion of cases excluded from analysis as
DCOs did not vary by year of diagnosis or by deprivation category.
Tumours of the ovary have usually been grouped with those of
the Fallopian tube, broad ligament and other uterine adnexa (ICD-
9 183, ICD-10 C56–57). Ovarian tumours were only assigned a
separate three-digit rubric in the International Classification of
Diseases with the introduction of the tenth revision in 1995 (ICD-9
183.0; ICD-10 C56), but in any case almost 99% of the tumours
were coded to the ovary, with only about 1% to the Fallopian tube
(183.2, C57.0); tumours coded to the broad ligament and other
adnexa were extremely rare. As is conventional, therefore, these
tumours were included with ovarian cancers in the survival
analyses, for consistency in the interpretation of long-term trends.
Adenocarcinomas accounted for most tumours that were
assigned to a specific morphology, with 39% coded to serous,
papillary or mucinous cystadenocarcinoma and 34% to other
specific types of adenocarcinoma; 20% were poorly specified
carcinomas.
SURVIVAL TRENDS
Relative survival at 1 year rose from 56% for women diagnosed
during 1986–1990 to 66% for those diagnosed during 1996–1999.
This represents a rapid and significant deprivation-adjusted
increase of about 5% every 5 years (Table 1). Five-year survival
rose from 30 to 38%, representing a statistically significant
increase of 3% every 5 years.
Short-term predictions based on hybrid analysis (Brenner and
Rachet, 2004) of patients’ survival experience during 2000–2001
suggest that the underlying increase in survival up to 5 years is
likely to continue (Table 1, Figure 1).
It is striking that relative survival at 10 years has remained low,
around 26%, for women who were diagnosed in both the late 1980s
and the early 1990s (Table 1, Figure 1). These estimates are based
on classical techniques of following up all or most of the women
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can yet be made for women diagnosed during 1996–1999. In
this case, however, hybrid analysis based on events during
2000–2001 suggests that a substantial increase in 10-year survival
can be expected within the next 5 years or so, to approximately 33%
(Figure 1). This is because 5-year survival increased much more
quickly between the early and late 1990s than over the previous
5 years (Table 1, Figure 1), and the hybrid estimate of 10-year survival
incorporates this recent jump in medium-term survival.
DEPRIVATION
Women living in more deprived areas who were diagnosed with
ovarian cancer in the late 1980s had lower survival than more
affluent women at both 1 and 5 years after diagnosis (Table 2). The
Table 1 Trends in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Women 56.0 (55.2, 56.6) 59.6 (59.0, 60.3) 65.8 (65.1, 66.5) 4.9** (3.6, 6.3) 66.6 (65.6, 67.5)
5 years Women 29.8 (29.1, 30.4) 31.1 (30.4, 31.7) 38.1 (37.3, 38.9) 2.9** (1.5, 4.3) 38.6 (37.6, 39.6)
10 years Women 25.6 (24.9, 26.2) 26.4 (25.7, 27.1)  0.3 ( 2.7, 2.2) 33.3 (32.2, 34.4)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
Table 2 Trends in the deprivation gap in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Women  5.1** ( 7.2,  3.1)  4.2** ( 6.1,  2.3)  4.6** ( 6.6,  2.7) 0.3 ( 1.2, 1.7)  5.1** ( 7.8,  2.3)
5 years Women  1.9 ( 3.8, 0.1)  1.7 ( 3.5, 0.2) 1.0 ( 1.4, 3.5) 1.4 ( 0.2, 3.0) 1.2 ( 1.8, 4.2)
10 years Women  1.1 ( 3.0, 0.8) 0.2 ( 1.8, 2.2) 1.3 ( 1.5, 4.1) 2.7 ( 0.4, 5.9)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by calendar
period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001. Survival estimated with cohort
or complete approach (1986–1990, 1991–1995, 1996–1999) or hybrid
approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative survival (%) by
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001.
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significantly wider at 1 year ( 5.1%) than at 5 years ( 1.9%).
Survival rose slightly more for women in the deprived categories
than for the more affluent groups. The deprivation gap in 1-year
survival fell slightly to  4.6%, and the deprivation gap in 5-year
survival disappeared, becoming positive (1.0%). These changes are
small, and not individually significant, but they appear systematic.
It is notable that the larger increase in 5-year survival in the late
1990s (Figure 1) is accompanied by a distinct flattening of the
deprivation gradient (Figure 2).
Short-term predictions of the socioeconomic gradient in ovarian
cancer survival suggest little imminent change (Table 2), with a
significant deficit in 1-year survival of  5% for the least affluent
women, but little difference in longer-term survival (Table 2).
COMMENT
The more recent improvement in survival is probably due to
progress in treatment. Only a minority of women are diagnosed
early enough for radical hysterectomy and oophorectomy alone to
be successful, and many women are given adjuvant chemotherapy.
Regimens combining taxanes (paclitaxel and docetaxel) with
platinum compounds are now generally recommended as first-line
treatment for women with advanced disease (Lister-Sharp et al,
2000). Evidence of effectiveness suggests that survival is improved
when surgery is done by specialists in gynaecological oncology and
when treatment is undertaken by expert multi-disciplinary teams
(NHS Centre for reviews and dissemination, 1999).
Survival at 1 year after diagnosis is lower for women living in
deprived areas: these women tend to have more advanced disease
at diagnosis (Brewster et al, 2001). However, the gradual
disappearance of the deprivation gap in 5-year survival by the
late 1990s – in contrast to the pattern for most other cancers
in women – suggests that deprived women diagnosed during
1996–1999 generally obtained at least as good access to optimal
treatment as affluent women.
Thus among the 17 different cancers in women examined in
these analyses, ovarian cancer was one of only five (with stomach,
pancreas, kidney, and the different types of leukaemia) for which
survival for women living in the poorest one-fifth of electoral
wards in England and Wales in the late 1990s was not lower than
for women in the richest fifth of wards. The proportion of DCO
cases was similar in each year and in each deprivation category
(data not shown); therefore, estimates of trend in the deprivation
gradient in survival are not likely to be biased as a result of their
exclusion from analysis. The deprivation-specific life tables used in
the analyses are the same as those used for all other cancers, for
most of which the deprivation gap in survival widened during the
1990s. Narrowing of the deprivation gap in survival from ovarian
cancer thus seems unlikely to be an artefact either of the data or of
our analytic approach.
Advanced stage at diagnosis frequently limits the potential
for radical treatment. Evidence from a large randomised controlled
trial indicates that earlier detection by screening does reduce
mortality (Jacobs et al, 1999). Mass screening for ovarian cancer
is being evaluated in the United Kingdom Collaborative Trial
of Ovarian Cancer Screening (UKCTOCS) (Lewis and Menon,
2003). This trial will compare two types of screening test (serum
CA125 and transvaginal ultrasound) with no test at all; it is due to
end in 2010.
Compared with many other common cancers, survival
from ovarian cancer did not improve greatly during the
1980s (Coleman et al, 1999). For women diagnosed in England and
Wales during the early 1990s, 5-year survival from ovarian cancer was
still 5–8% below the age-standardised European average relative
survival of 37% (Sant et al, 2003). It remains to be seen whether the
improvement in survival during the late 1990s will have narrowed
the gap with the European average survival.
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